Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?

doi:10.1200/JCO.22.01199

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2023

Benjamin David J, Nagasaka Misako

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 36095291
DOI: 10.1200/JCO.22.01199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?PMID 36095291Read ↗

A vanishing act: the incredible erlotinib.Semantic proximity Read ↗

Will kinase inhibitors have a dark side?Semantic proximity Read ↗

RETaliation-Tackling Rare Resistance Alterations to Osimertinib.Semantic proximity Read ↗

Afatinib for lung cancer: let there be light?Semantic proximity Read ↗

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read ↗

[Revocation of the BRCA1 patents by the European Office of Patents: a victory over a rights abuse].Semantic proximity Read ↗

Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily betterSemantic proximity Read ↗

Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.